USD 4.23
(-10.19%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 4.09 Million USD | 10.16% |
2022 | 3.6 Million USD | 39.74% |
2021 | 2.57 Million USD | 30.98% |
2020 | 1.96 Million USD | 10.18% |
2019 | 1.78 Million USD | -25.6% |
2018 | 2.4 Million USD | 115.23% |
2017 | 1.11 Million USD | -36.23% |
2016 | 1.75 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 1.11 Million USD | -11.28% |
2024 Q2 | 1.41 Million USD | 31.07% |
2023 Q1 | 826 Thousand USD | 1.1% |
2023 Q3 | 956 Thousand USD | 2.03% |
2023 Q2 | 937 Thousand USD | 13.44% |
2023 FY | 3.97 Million USD | 10.16% |
2023 Q4 | 1.25 Million USD | 31.69% |
2022 Q3 | 1.18 Million USD | 44.69% |
2022 Q2 | 819 Thousand USD | 3.67% |
2022 Q1 | 790 Thousand USD | -20.28% |
2022 Q4 | 817 Thousand USD | -31.05% |
2022 FY | 3.6 Million USD | 39.74% |
2021 Q4 | 991 Thousand USD | 79.2% |
2021 Q1 | 478 Thousand USD | 28.84% |
2021 Q2 | 557 Thousand USD | 16.53% |
2021 Q3 | 553 Thousand USD | -0.72% |
2021 FY | 2.57 Million USD | 30.98% |
2020 Q2 | 455 Thousand USD | -21.01% |
2020 Q1 | 576 Thousand USD | 108.7% |
2020 Q4 | 371 Thousand USD | -34.57% |
2020 FY | 1.96 Million USD | 10.18% |
2020 Q3 | 567 Thousand USD | 24.62% |
2019 Q2 | 1 Million USD | 99.8% |
2019 FY | 1.78 Million USD | -25.6% |
2019 Q4 | 276 Thousand USD | 0.0% |
2019 Q3 | - USD | -100.0% |
2019 Q1 | 504 Thousand USD | -24.66% |
2018 FY | 2.4 Million USD | 115.23% |
2018 Q3 | 744 Thousand USD | 30.07% |
2018 Q4 | 669 Thousand USD | -10.08% |
2018 Q1 | 495 Thousand USD | 45.16% |
2018 Q2 | 572 Thousand USD | 15.56% |
2017 FY | 1.11 Million USD | -36.23% |
2017 Q4 | 341 Thousand USD | 0.0% |
2016 FY | 1.75 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Akoya Biosciences, Inc. | 104.27 Million USD | 96.072% |
AngioDynamics, Inc. | 252.41 Million USD | 98.377% |
AtriCure, Inc. | 327.05 Million USD | 98.748% |
Avinger, Inc. | 18.63 Million USD | 78.023% |
Azenta, Inc. | 336.26 Million USD | 98.782% |
BioLife Solutions, Inc. | 117.57 Million USD | 96.516% |
The Cooper Companies, Inc. | 1.82 Billion USD | 99.776% |
Daxor Corporation | 1.28 Million USD | -219.871% |
Ekso Bionics Holdings, Inc. | 24.19 Million USD | 83.068% |
Femasys Inc. | 15.2 Million USD | 73.053% |
GlucoTrack, Inc. | 7.1 Million USD | 42.342% |
Harvard Bioscience, Inc. | 58.58 Million USD | 93.008% |
Hologic, Inc. | 1.34 Billion USD | 99.696% |
ICU Medical, Inc. | 717.04 Million USD | 99.429% |
Intuitive Surgical, Inc. | 2.96 Billion USD | 99.862% |
KORU Medical Systems, Inc. | 26.1 Million USD | 84.311% |
LeMaitre Vascular, Inc. | 90.33 Million USD | 95.466% |
Innovative Eyewear, Inc. | -119.32 Thousand USD | 3532.527% |
Innovative Eyewear, Inc. | -119.32 Thousand USD | 3532.527% |
Masimo Corporation | 867 Million USD | 99.528% |
Microbot Medical Inc. | 9.85 Million USD | 58.437% |
Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | 77.763% |
Merit Medical Systems, Inc. | 459.92 Million USD | 99.109% |
Nephros, Inc. | 9.78 Million USD | 58.136% |
NovoCure Limited | 613.92 Million USD | 99.333% |
NEXGEL, Inc. | 4.09 Million USD | 0.0% |
Singular Genomics Systems, Inc. | 102.24 Million USD | 95.994% |
OraSure Technologies, Inc. | 125.34 Million USD | 96.732% |
Pro-Dex, Inc. | 7.37 Million USD | 44.484% |
Pulse Biosciences, Inc. | 43.57 Million USD | 90.6% |
Predictive Oncology Inc. | 15.22 Million USD | 73.105% |
Precision Optics Corporation, Inc. | 8.52 Million USD | 51.937% |
QuidelOrtho Corporation | 1.35 Billion USD | 99.698% |
Repligen Corporation | 261.12 Million USD | 98.431% |
Sanara MedTech Inc. | 61.12 Million USD | 93.299% |
STAAR Surgical Company | 224.55 Million USD | 98.176% |
Sharps Technology, Inc. | 10.12 Million USD | 59.552% |
Utah Medical Products, Inc. | 13.26 Million USD | 69.112% |
DENTSPLY SIRONA Inc. | 1.79 Billion USD | 99.772% |
Jin Medical International Ltd. | 3.91 Million USD | -4.555% |